PTPN11 and Miyoshi myopathy: As reported, SHP2 is indispensable for the activation of the RAS/ERK pathway and might play an oncogenic role in MM for the reason that SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in MM cells, and its level is associated with poor response to induction therapy and prognosis of MM (Chauhan et al., 2000; Beldi-Ferchiou et al., 2017).